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A clinical study conducted in Canada compared two methods of estimating exposure to cigarette smoke
in 192 volunteer subjects: 43 smokers of 4–6 mg, 49 of 8–12 mg and 50 of 14–15 mg ISO tar yield
cigarettes and 50 non-smokers. Estimates of mouth level exposure (MLE) to nicotine, 4-(methylnitrosa-
mino)-1-(3-pyridyl)-1-butanone (NNK), pyrene and acrolein were obtained by chemical analysis of spent
cigarette ﬁlters. Estimates of smoke constituent uptake were achieved by analysis of urinary biomarkers
for total nicotine equivalents (nicotine, cotinine, trans–30-hydroxycotinine plus their glucuronide conju-
gates), NNK (total 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) plus glucuronide), pyrene
(1-hydroxy pyrene plus glucuronide) and acrolein (3-hydroxylpropyl-mercapturic acid) plus the nicotine
metabolite cotinine in plasma and saliva. The objective of our study was to conﬁrm the correlations
between measures of human exposure obtained by ﬁlter analysis and biomarkers. Signiﬁcant correlations
(p < 0.001) were found between MLE and the relevant biomarker for each smoke constituent. The
adjusted values of the Pearson correlation coefﬁcients (r) were 0.80 (nicotine), 0.77 (acrolein) and 0.44
(pyrene). NNK correlations could not be obtained because of the low NNK yield of Canadian cigarettes.
Unexpectedly high levels of acrolein biomarker found in non-smokers urine on one of the two days
sampled emphasised the need for more than one sampling occasion per period and an awareness of
non-tobacco sources of smoke constituents under investigation. No consistent dose response, in line with
ISO tar yield smoked, of MLE estimates was found for nicotine, pyrene and acrolein and respective
biomarkers. The inﬂuence of demographics on our results has also been examined.
 2010 Elsevier Inc. Open access under CC BY-NC-ND license.1. Introduction duplication, ﬁlter analysis and biomarkers of exposure. The ﬁrstSmoking machines are currently used to evaluate the amount of
tar and nicotine generated by a cigarette smoked under prescribed
regimes. More than forty years ago, the United States Federal Trade
Commission (FTC) recognized that these machines could not be
used to estimate human exposure to inhaled tar and nicotine
(Federal Trade Commission, 1967).
Methods have therefore been developed to estimate human cig-
arette smoke yield and dose, including pufﬁng topography and3-hydroxypropylmercapturic
mmission; ISO, International
hromatography with tandem
mouth level exposure; NNAL,
K, 4 (methylnitrosamino)-
otentially reduced-exposure
PM, total particulate matter.
h and Development, Imperial
t, Montreal, QC, Canada H4C
-NC-ND license.of these involves recording human pufﬁng behaviour during smok-
ing, followed by accurate duplication of this smoking record using a
specialised smoking machine and a second cigarette having the
same characteristics as the one smoked by the human subject.
The smoke produced by this matched cigarette can be analysed to
provide an estimate of the smoker’s mouth level exposure (MLE)
of smoke constituents (Comer and Creighton, 1978). Filter analysis
provides an estimate of smokers MLE through an analysis of the
amount of nicotine (and other smoke constituents) retained on
the ﬁlter plus knowledge of the ﬁltration efﬁciency of the cigarette
ﬁlter. Methods based on this principle have been described in detail
elsewhere (St. Charles et al. (2006 ,2009), Shepperd et al. (2006),
Watson et al. (2004), Polzin et al. (2009)). The levels of biomarkers
of exposure (typically cigarette smoke constituent metabolites) in
urine, saliva and blood can be used to provide an indication of the
amount of smoke constituent taken up into the smokers’ body
(Benowitz, 1996; Hatsukami et al., 2006; St. Charles et al., 2006).
The relative merits of these three approaches were reviewed by
Shepperd et al. (2009) in a report on a study that compared the
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Germany, recruited smokers of US blended-style cigarettes. The
ﬁndings indicated that estimates of exposure obtained by ﬁlter
analysis were signiﬁcantly correlated with those obtained by mea-
suring biomarkers. It was concluded that ﬁlter analysis may pro-
vide an informative alternative to biomarkers for estimating
exposure. This observation has recently been supported by the re-
view of Pauly et al. (2009).
The objective of our study was as that of Shepperd et al. (2009)
i.e. to determine if MLE estimates obtained from ﬁlter analysis cor-
relate with estimates of exposure as determined using biomarkers
in smokers of cigarettes of three different ISO Nicotine Free Dry
Particulate Matter (NFDPM or tar) yields. The two studies differ
in that Shepperd et al. (2009) conducted their clinical study in
Germany with smokers of 1–2, 4–6 and 9–10 mg ISO tar yield cig-
arettes containing US blended styles of tobacco, whilst our study
was conducted in Canada with smokers of 4–6, 8–12 and 14–
15 mg ISO tar yield cigarettes containing ﬂue-cured tobacco. The
very limited pool of Canadian smokers of 1–2 mg ISO tar yield cig-
arettes did not make their recruitment possible.2. Materials and methods
2.1. Study design
The study was as described by Shepperd et al. (2009), except that
subject recruitment and all clinical aspects of this study were con-
ducted by MDS Pharma Services, Montreal, Canada. One hundred
and ninety two healthy volunteer subjects were recruited into the
study; 142 smokers and 50 non-smokers. The protocol and informed
consent forms were approved by an Institutional Review Board con-
vened at MDS Pharma Services and the clinical study was conducted
in accordance with the latest version of the World Medical Associa-
tion Declaration of Helsinki (World Medical Association, 2004) and
ICH Harmonized Tripartite Guidelines for Good Clinical Practice
1996. It was agreed with the ethics committee that subjects would
be paid a stipend of 2140 CAN$ for their participation in the study.
For the duration of the study, smokers smoked a supplied prod-
uct of cigarette of the same blend style and ISO tar within 2 mg of
their normal product. Smokers were required to change products
for this study, and subjects were given 5 days acclimatisation on
the supplied cigarette before any measures were taken. Any behav-
ioural changes that might have remained would not have affected
the primary objective which was to correlate the exposure esti-
mates between the two methods employed in the study. This
was not a survey into smoke exposure in Canadian smokers smok-
ing their normal brand. As described by Shepperd et al. (2009)
there are several technical advantages for the ﬁlter analysis
approach in using a single supplied product for each group, includ-
ing reducing the number of calibration curves required to a man-
ageable level, ensuring that calibrations were prepared with the
same cigarettes smoked by subjects, having a full knowledge of
the history of the cigarettes and allowing detailed smoke chemis-
try to be determined on the cigarettes smoked during the study.
Like Shepperd et al. (2009), the study included both ambulatory
and clinical periods (Fig. 1). The ambulatory periods allowed accli-
matisation to the cigarettes while the clinical conﬁnement periods
ensured compliance and facilitated complete collection of 24 h
urine, cigarette ﬁlters and daily cigarette consumption data.
2.2. Product selection
Three commercial cigarette products were selected in the range
of ISO tar yields legally sold in Canada. They were composed of a
Virginia ﬂue-cured tobacco blend, were of a design typical of theCanadian market and were commercially available in Canada
(Table 1). In each case the supplied and tested products were
sourced from the same manufacturing batch, either at the point
of manufacture or veriﬁed by batch code at the point of sale.
2.3. Subject selection
Subjects were recruited according to the following criteria;
Smokers inclusion criteria speciﬁed that smoking subjects should
(1) be regular smokers whose chosen brand was within one of the
ISO tar bands shown in Table 1 and of a type/format typical of the
Canadian market; (2) been smoking their chosen brand for at least
six months (3) have smoked cigarettes for at least three years. Self-
reported cigarette consumption should be six to thirty cigarettes
per day for group 4 (to facilitate recruitment) and ten to thirty cig-
arettes per day for groups 9 and 14. Subjects were selected if they
met universal inclusion/exclusion criteria, including, (a) being
22 years of age or older (b) weighing at least 52 kg for males and
45 kg for females, (c) having no clinically signiﬁcant abnormal ﬁnd-
ings, as judged by the Principal Investigator, (d) demonstrating
ability to comprehend the Informed Consent Form, ability to com-
municate well with the Principal Investigator, to understand and
comply with the requirements of the study, and be judged suitable
for the study in the opinion of the Principal Investigator, (e) no use
of any nicotine or tobacco products other than ﬁltered cigarettes, (f)
no use of any drugs or substances known to inﬂuence the metabo-
lism of smoke constituents of interest (g) females not pregnant or
lactating and using reliable contraception for the duration of the
study. Inclusion criteria for the non-smoking group speciﬁed that
individuals should have never smoked and meet criteria (a)–(g)
above. A ratio of male to female between 3:2 and 2:3 and a similar
age distribution within each group were targeted.
Subjects were screened at the clinic between 28 and 2 days
prior to their start on the study. Screening included: obtaining
informed consent; medical history; demography; a physical exam-
ination; pulmonary function testing and clinical laboratory tests,
which included a serum pregnancy test for females and urine
screen for cotinine for non-smokers. Smoking history included
self-reported daily consumption and taking a photocopy of the
subject’s normal cigarette pack, which was checked against a list
of acceptable brands provided by the sponsor.
2.4. Home smoking
Subjects were supplied with cigarettes for home smoking dur-
ing the ambulatory sections of this study at day 1 (study start)
and after the ﬁrst clinical conﬁnement period (day 7). Subjects
were permitted to smoke ad libitum throughout the study. There-
fore, each subject’s home smoking supply was based on their
claimed daily consumption, rounded to the nearest whole pack,
plus two packs for the whole home smoking period). This ensured
that subjects were not supplied with excessive cigarettes, although
they could request more if they ran out. Daily cigarette consump-
tion was recorded by subjects in a diary.
2.5. Filter collection
Filter collection was performed in the clinic as described by
Shepperd et al. (2009). Smoking subjects were permitted to smoke
only in a designated room set aside exclusively for the purpose.
This roomwas equipped with an air ﬁltration system. Before enter-
ing the room, the smoker was issued with a cigarette and, on leav-
ing, the spent ﬁlter was collected. Upon receipt, a member of the
clinical staff cut a 10 mm tip section from the mouth-end of the
ﬁlter using a custom ﬁlter cutter. The 10 mm tip was retained in
an airtight labelled aluminium tin and the remainder of the ﬁlter
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Fig. 1. Study design ﬂow diagram.
Table 1
Cigarette product details.
Group
4 9 14
Subject chosen product
ISO tar band, mg/cig 4–6 8–12 14–15
ISO nicotine, mg/cig 0.4–0.5 0.8–1.2 1.2–1.5
Blend style FCa FC FC
Format King size King size King size
Supplied commercial product
Blend style FC FC FC
Format King size King size King size
Pack Tar/Nicotine/CO yields, mg/cig 4/0.4/5 9/0.9/9 14/1.3/16
ISO yields
Tar, mg/cig 3.8 8.4 13.4
Nicotine, mg/cig 0.44 0.90 1.15
CO, mg/cig 3.8 8.8 14.7
NNK, ng/cig <8.0b <8.0b 10.5
Acrolein, lg/cig 22.5 48.8 86.5
Pyrene, ng/cig 25 41.1 52.3
Design
Filter ventilation,% 64 34 0
Paper permeability, CUc 80 80 60
Total open pressure drop mmWG 79 106 124
a Flue-cured Virginia tobacco.
b Limit of quantitation (LOQ).
c CORESTA units.
Table 2
Filter analysis calibration regime selection – human nicotine and ‘tar’ MLE estimation
(T: ﬁlter tipping).
Regime No Volume
(mL)
Duration
(s)
Interval
(s)
Average
ﬂow (mL/s)
Smoked
length/puffs
0 – – – – –
1 40 2 60 20 4 puffs
2 40 2 30 20 T + 3 mm
3 50 1.5 60 33.3 T + 3 mm
4 50 1.5 30 33.3 T + 3 mm
5 70 1.5 60 46.7 4 puffs
6 70 1.5 30 46.7 T + 3 mm
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period (typically 19:00 to 18:59 h) were collected in the same
tin, which was stored at room temperature for up to 24 h before
being dispatched by air freight to the British American Tobacco
laboratories in Southampton, UK, for analysis.
2.6. Filter analysis
Filters were analysed to estimate mouth level exposure to nic-
otine and NNK, pyrene and acrolein as described by Shepperd
et al. (2009). Mouth level estimates of NFDPM were also obtained
for this study. The methodology used to estimate MLE of nicotine
and NFDPM is described in greater detail by St.Charles et al. (2009).
2.7. Estimating nicotine and NFDPM (‘tar’) MLE
For each of the three cigarette types, calibration curves were
prepared by machine smoking cigarettes using six separate re-gimes (Table 2) selected to provide a range of yields that covered
the anticipated human yields and ﬁlter tip levels. Un-smoked ﬁlter
tips were used as blanks (regime 0).
Mainstream smoke yields of Total Particulate Matter (‘TPM’),
nicotine, water and NFDPM were determined at each regime
according to ISO methods 3308, 4387, 10362-1 and 10315.
Cigarette ﬁlter tips collected from each calibration regime, as
well as those from each 24 h human smoking period at the clinic
were analysed for nicotine content as described by Shepperd et al.
(2009) and St.Charles et al. (2009). In this method a calibration
curve is prepared by plotting nicotine yield (mg/cigarette) at each
calibration regime against nicotine per tip (mg/tip). The calibration
is linear and the linear regression equation is used to estimate the
subject’s nicotine yield (or nicotine MLE) from the nicotine content
of subject’s ﬁlter tips. In our study, 87% of tips from group 4 and 99%
from groups 9 and 14 were within the calibration range.
The UV absorbance at 310 nm of each calibration and human ﬁl-
ter tip extract was also determined to provide a calibration curve
by plotting NFDPM (mg/cigarette) against UV absorbance of ﬁlter
tip extract. The resultant linear regression equation was used to
estimate the subject’s NFDPM yield (or NFDPM MLE) from the
UV absorbance of the subject’s ﬁlter tip extracts. This methodology
is described in greater detail by St.Charles et al. (2009).
2.8. Estimating NNK, pyrene and acrolein MLE
Calibration curves for estimation of MLE to NNK, acrolein and
pyrene were also prepared as described by Shepperd et al. (2009)
except that three smoking regimes were used, namely ISO, Massa-
chusetts intense (Commonwealth of Massachusetts, 2004) and
Canadian intense (Health Canada 1999).
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Fig. 2. Distribution of smokers within groups 4, 9 and 14 according to their
reported smoking habits as expressed by ISO tar yield.
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Mainstream cigarette smoke was analysed for NNK, pyrene and
acrolein content as described by Shepperd et al. (2009).
2.10. Urine collection and analyses
Twenty four hour urine samples were collected from 7.00 pm
until 6.59 pm on the following day, thereby ensuring the sample
included one ﬁrst void and that the period coincided with the
cigarette ﬁlter collection period. This sample was analysed for
total nicotine, total cotinine and total trans-30-hydroxycotinine
(summed and reported as molar total nicotine equivalents, TNeq),
total 4-(methylnitrosoamino)-1-butanol (NNAL), 3-hydroxypropyl
mercapturic acid (HPMA) and total 1-hydroxypyrene (1-OHP) as
described by Shepperd et al. (2009).
2.11. Saliva and plasma collection and analyses
Saliva and plasma samples were collected and analysed for coti-
nine as described by Shepperd et al. (2009).
2.12. Statistical analysis
Minitab (v. 15) was used for statistical analyses as described by
Shepperd et al. (2009). For each smoker subject, a pooled mean
from the four 24 h results from period 1 (days 6 and 7) and period
2 (days 18 and 19) of clinical conﬁnement were used in the statis-
tical analysis for both MLE and biomarkers. (For non-smokers, this
was a mean from their one period of clinical conﬁnement: days 11
and 12).
3. Results
Of the 192 subjects recruited, results from 188 subjects were
used (49 in group NS, 42 in group 4, 48 in group 9 and 49 in group
14). Data not included were from two subjects who chose to with-
draw from the study, one subject who was removed by the princi-
pal investigator due to an adverse event not related to the study
and one subject who withdrew consent. The average age of sub-
jects was 40. Smokers self-reported smoking an average of 17 cig-
arettes per day. In each group more than 50% of recruited subjects
were male (Table 3).
Distribution of tar yields smoked within groups 4, 9 and 14 mg
is indicated in Fig. 2. Within these groups, 64%, 10% and 16% of
them smoked the supplied commercial product prior to the
recruitment, respectively.
The design of the study allowed a wide range of mouth level
exposures to nicotine, acrolein and pyrene, to be achieved and
for the corresponding urinary biomarkers: total nicotine equiva-
lents; NNAL; 3-HPMA and 1-OHP, as well as plasma and saliva coti-
nine (Table 4). The NNK MLE’s were also determined from a
calibration curve, mainstream NNK vs tip nicotine. However, since
50% of the mainstream NNK yields that were determined during
calibration were below the limit of quantitation, no robust calibra-
tion curve could be established to estimate NNKMLE. Therefore, no
levels of NNK MLE are reported.Table 3
Demographics and self-reported smoking habit.
No. subjects Gender Age Cigarettes per day
Group n % male Mean (min–max) Mean (min–max)
4 42 71 38 (22–60) 16.8 (10–30)
9 48 63 42 (22–60) 17.0 (8–30)
14 49 59 39 (22–64) 16.9 (10–30)
NS 49 55 41(22–71) n/aSubject to subject, within subject and within brand variation,
calculated using nested ANOVA and expressed as standard devia-
tion and %CV, are also shown in Table 5. A few subjects with incom-
plete data for all timepoints were removed, as indicated in the table
footnotes, to balance the data thus satisfying the statistical require-
ments for this analysis. Of note is the variation for the non-smoker
group for 3-HPMA where within subject variation far exceeds be-
tween subject variation. All subjects except one (98%) had signiﬁ-
cantly higher 3-HPMA levels on day 11 (mean 1410 ± 525 lg/
24 h) compared to day 12 (mean 557 ± 285 lg/24 h). This very high
intra-subject variability accounts for most of the variation in the
non-smoking group and this gives rise to relatively near-zero in-
ter-subject variation. Consequently, the inter-subject variation is
quoted as being the same as intra-subject variation.
To investigate the correlation between the two methods used to
estimate human smoke exposure, the biomarker levels for each
smoke constituent were plotted against mouth level exposures
(MLE) (Fig. 3). The regression lines bordered by 95% prediction
intervals were calculated from smoker data. Non-smoker data
were plotted for reference but have not been included in the
regression analysis.
Regression analysis showed positive linear relationships across
all biomarkers/mouth level exposure correlations with p < 0.05 in
all cases (Fig. 3; Table 6). This demonstrated that when MLEs in-
creased, the biomarkers also increased regardless of the product
smoked. This was true for both males and females. The Pearson
correlation coefﬁcients, r, were as good for females and males.
Regression analyses were also performed to estimate correla-
tion between MLE tar (NFDPM) and the MLE of other smoke con-
stituents (Table 7). Strong positive correlations (rP 0.90) were
observed between MLE tar and all others smoke constituents.
The correlation between MLE tar and levels of biomarkers was gen-
erally good with r values ranging between 0.5–0.8. In contrast, the
correlation between MLE tar and ISO smoking yield was generally
weak (r ranging between 0.06–0.43).
Mean data obtained by both methods (MLE vs biomarkers) from
male subjects were always higher than the female ones (Table 8).
4. Discussion
The objective of the present study has been fulﬁlled in that esti-
mates of exposure have been obtained by ﬁlter analysis and bio-
markers in smokers of cigarettes of three different tar bands, and
the correlation between the two methods established. The Pearson
correlation coefﬁcient for nicotine MLE vs TNeq (r = 0.80) was
found to be comparable to those reported by St.Charles et al.
(2006) (r = 0.91) in the US and by Shepperd et al. (2009)
Table 4
Filter analysis, biomarker and cigarette consumption data – mean (95% CI).
Group ANOVA# smokers p-value
NS 4 9 14
Filter analysis data
Nicotine MLE, mg/24hr n/a§ 28.6 (25.5–31.8) 30.2 (27.3–33.1) 34.1 (31.5–36.7) 0.025
Acrolein MLE, lg/24hr n/a§ 1880 (1646–2114) 1773 (1600–1946) 2253 (2084–2422) 0.001 (a,b)
Pyrene MLE, ng/24hr n/a§ 1214 (1099–1330) 1263 (1148–1378) 1515 (1390–1640) 0.001 (a,b)
NFDPM MLE mg/24hr n/a§ 244 (213–276) 239 (214–264) 321 (294–348) <0.001 (a,b)
Biomarker data
TNeq, mg/24hr 0.03 (0.02–0.03)$ 14.5 (12.7–16.2) 15.1 (13.4–16.8) 18.9 (17.4–20.5) <0.001 (a,b)
NNAL, ng/24hr 10 (9–11)$ 213 (178–248) 176 (147–204) 252 (220–284) 0.003 (a)
3-HPMA, lg/24hr 983 (879–1088) 1973 (1739–2207) 1868 (1614–2121) 2494 (2252–2735) 0.001 (a,b)
1-OHP, ng/24hr 91 (72–109) 334 (292–375) 276 (244–309) 350 (315–385) 0.011 (a)
Saliva cotinine
0700 h, ng/mL 0.2 (0.1–0.2)$ 240 (205–275) 269 (238–299) 306 (273–340) 0.025 (a)
1700 h, ng/mL 0.2 (0.1–0.2)$ 266 (229–304) 298 (264–331) 334 (302–366) 0.029
Plasma cotinine
0700 h, ng/mL 0.3 (0.3–0.3)$ 237 (205–269) 247 (222–273) 285 (258–313) 0.046
1700 h, ng/mL 0.3 (0.2–0.3)$ 242 (208–275) 254 (228–280) 291 (265–318) 0.045
Cigarette consumption data
Cigarettes per day n/a§ 18.8 (17.5–20.1) 17.9 (16.3–19.4) 17.7 (16.6–18.9) 0.501
§ n/a – Not applicable, by deﬁnition, MLE and cigarettes per day for non-smokers are zero.
$ >90% of these results reported as below limit of quantitation (LOQ). ½ LOQ used in calculations.
# ANOVA for comparison of smoker data only – Letters in brackets designate different statistical groups at p 6 0.05 (a) (group 14 different from group 9) and (b) (group 14
different from group 4).
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vs salivary cotinine (r = 0.66 Canada; r = 0.73 US; r = 0.79 Ger-
many), and for nicotine MLE vs plasma cotinine (r = 0.68 Canada;
r = 0.83 Germany), were generally lower than those for MLE vs
TNeq. This might be due to the fact that saliva and plasma were
sampled at single time points rather than a collected amount of
24 h excreted urine (Höfer et al. 1991, 1992). Also, since the coti-
nine measurements were concentrations rather than absolute
amounts, some additional variability may have arisen from varia-
tion in subject body size. A positive correlation was also found be-
tween TNeq and salivary cotinine (r = 0.63) as previously reported
(r = 0.74; US; r = 0.73; Germany). A strong correlation (r = 0.97)
was also found between salivary and plasma cotinine concentra-
tions as previously reported (r = 0.99; UK; r = 0.95; Germany). For
further studies, estimation of cotinine could be done by salivary
sampling only because it is less invasive than blood sampling.
We found that cotinine in saliva was higher than in plasma, as pre-
viously reported by Jarvis et al. (2003). However our difference was
15% (SD = 10) whereas Jarvis et al. reported a 25% difference. In
summary, the relationships between biomarker levels and MLE,
and plasma and saliva cotinine and total nicotine equivalents were
similar or the same as previously published (Shepperd et al., 2009).
In addition, the relationship between plasma and saliva cotinine
was also in keeping with previously published data (Jarvis et al.,
2003; Shepperd et al., 2009). In this study the recovery of nicotine
MLE as total urinary nicotine equivalents was low. This may have
been due to an over estimate of nicotine MLE, or an underestima-
tion of nicotine and metabolites in the urine or differences in
smoking behaviour as pointed out by Shepperd et al. (2009).
Although the mean levels of NNAL in all smoking groups were
above the limit of quantitation, we were unable to quantify the
NNK MLE due to its very low level in ﬂue-cured tobacco smoke
(Table 1) with two products yielding NNK levels below the limit
of quantitation when smoked under ISO conditions. This limitation
of the method used to determine NNK in mainstream tobacco
smoke meant that it was also not possible to establish correlations
between MLE NNK and its metabolite NNAL. Improvement in sen-
sitivity of the mainstream NNK method should be considered forfuture studies on cigarettes containing such low NNK ﬂue-cured
tobacco blends.
Estimates of exposure to other smoke components such as acro-
lein and pyrene were correlated to their respective metabolite i.e.
3-HPMA and 1-OHP respectively. The scatter observed in the acro-
lein and pyrene correlation may be attributed to the greater range
of background 3-HPMA and 1-OHP levels as shown by the non-
smokers. Acrolein exposure through cigarette smoke is generally
considered to make up a large proportion of total human exposure.
Acrolein originates from the combustion of carbohydrates present
in tobacco at levels up to 20% (Stevens and Maier, 2008). Published
values of excreted 3-hydroxypropylmercapturic acid (3-HPMA),
the main urinary metabolite of acrolein, are about 250 lg/24 h
for non-smokers (Roethig et al. 2007; Shepperd et al. 2009). Esti-
mated acrolein atmospheric exposure was reported to be 154 lg/
24 h (Stevens and Maier, 2008) which was estimated to be the
acrolein amount generated by smoking 2.5 cigarettes (Carmella
et al. 2007). This estimation was based on Roemer et al’s paper
which describes acrolein yield of conventional cigarettes ranging
from 54 to 155 lg/cigarette (Roemer et al., 2004). In the non-smo-
ker group we found levels of 3-HPMA to be almost twice the values
reported by Roethig et al. (2007) and Shepperd et al. (2009) on day
12 and more than 5 times higher for day 11. Further investigation
of the day 11 samples, including repeat analysis, conﬁrmed the
high 3-HPMA levels for these samples. This suggests that sources
of acrolein other than tobacco smoke have been involved in our
study. These could include carbohydrates (Amadori products, lipid
peroxidation), lipids (glycerol, fatty acids), amino acids (methio-
nine, threonine), polyamines (spermine, spermidine), acrolein
emissions from food cooking (Stevens and Maier, 2008), gasoline
and diesel exhaust, aircraft and industrial emissions (Carmella
et al., 2007). In our study, despite investigation into diet and pos-
sible sources of environmental contamination within the clinic,
we could not pinpoint the source of the high level of acrolein. All
future studies should ensure that all sources of interference are
eliminated where possible. This unexpected ﬁnding does however
emphasise the importance of using more than one day sampling
per period and of including non-smoker groups in smoker studies
Table 5
Variability: within subject, between subject and within group (brand) standard deviation (%cv).
Group
NS 4 9 14
N Within
subject
Between
subject
N Within
subject
Between
subject
Within
group
N Within
subject
Between
subject
Within
group
N Within
subject
Between
subject
Within
group
Filter analysis data
Nicotine MLE,
mg/24hr
n/aa n/aa 42 5.7 (20) 10.0 (35) 11.5 (40) 48 5.5 (18) 9.8 (32) 11.3(37) 49 5.7 (17) 8.8 (26) 10.4 (31)
Acrolein MLE,
lg/24hr
n/aa n/aa 42 395 (21) 747 (40) 845 (45) 48 331 (19) 588 (33) 675 (38) 49 375 (17) 574 (25) 686 (30)
Pyrene MLE,
ng/24hr
n/aa n/aa 42 228 (19) 364 (30) 429 (35) 48 224 (18) 392 (31) 452 (36) 49 255 (17) 428 (28) 498 (33)
Biomarker data
TNeq, mg/24hr n/cb n/cb 40c 2.9 (20) 5.7 (39) 6.4 (44) 46c 3.3(22) 5.7 (38) 6.6 (44) 44d 3.0 (16) 5.5 (29) 6.3 (33)
NNAL, ng/24hr 49 2.0 (20) 4.4 (44) 40c 36 (17) 114 (53) 120 (56) 46c 32 (18) 100 (57) 105 (60) 44d 36 (14) 113 (45) 119 (47)
3-HPMA, lg/24hr 49 662 (68) 662 (68) 40c 434 (22) 756 (38) 871 (44) 46c 411 (22) 864 (46) 957 (51) 44d 411 (16) 825 (33) 922 (37)
1-OHP, ng/24hr 49 19 (21) 45 (50) 40c 128 (38) 196 (59) 234 (70) 46c 69 (25) 112 (40) 131 (47) 44d 54 (16) 119 (34) 131 (38)
Saliva cotinine
0700 h, ng/mL n/cb n/cb 42 53 (22) 114 (47) 126 (52) 48 62 (23) 103 (38) 120 (45) 48e 61 (20) 118 (39) 133 (43)
1700 h, ng/mL n/cb n/cb 42 55 (21) 122 (46) 134 (50) 48 66 (22) 115 (39) 132 (44) 49 64 (19) 110 (33) 128 (38)
Plasma cotinine
0700 h, ng/mL n/cb n/cb 42 41 (17) 104 (44) 112 (47) 48 49 (20) 87 (35) 99 (40) 49 45 (16) 96 (34) 106 (37)
1700 h, ng/mL n/cb n/cb 42 42 (17) 109 (45) 117 (48) 47e 49 (19) 90 (36) 103 (41) 49 45 (15) 93 (32) 103 (35)
Cigarette consumption data
Cigarettes per day n/aa n/aa 42 3.3 (18) 4.1 (22) 5.3 (28) 48 3.2 (18) 5.2 (29) 6.1 (34) 49 3.2 (18) 3.7 (21) 4.9 (28)
a n/a – Not applicable, by deﬁnition MLE for non-smokers is zero.
b n/c – Not calculated as >90% of these results reported as below limit of quantitation (LOQ).
c 2 Subjects removed as results only available for 3 out of 4 days.
d 5 Subjects removed as results only available for 3 out of 4 days.
e 1 Subject removed as results only available for 3 out of 4 days.
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Fig. 3. Scatterplots of biomarker vs estimated mouth level exposure showing regression lines bordered by 95% prediction intervals. Key to scatterplot groups:
NS – s; 4 – +; 9 – e;14 –N.
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tion (r = 0.44) was observed between pyrene and 1-OHP as ob-
served and discussed by Shepperd et al. (2009) (r = 0.63). Pyrene
is not a tobacco-speciﬁc compound; thus, there are other sources
of pyrene than cigarette smoke (Hecht, 2002). In previous studies,
levels of 1-OHP were shown to decrease in urine upon smoking
cessation but did not disappear because the subjects were exposed
to other sources of pyrene from the diet, polluted air and occupa-
tional settings (Hecht et al., 2004, 2005). This was explained by
considerably variable levels of 1-OHP reported in non-smokers
from 0.03 to 0.27 lmol/mol creatinine compared to 0.04 to
0.57 lmol/mol creatinine in smokers (Hecht, 2002). Metabolic
polymorphisms have also been shown to inﬂuence the levels of
urinary 1-OHP (Nan et al., 2001).
The Shepperd et al. (2009) data showed a dose response in line
with ISO tar yield for both MLE (nicotine, NNK, pyrene, acrolein)
and their respective biomarkers (total nicotine equivalents (TNeq)
and cotinine, NNAL, 1-OH pyrene and 3-HPMA). Shepperd et al’s
ﬁndings conﬁrmed those of a study conducted in the United States
by St.Charles et al. (2006) who also showed positive correlations
between FTC nicotine yields, nicotine MLE, and urinary nicotine
metabolite levels. We observed that MLE estimates and biomarkers
of 14 mg smokers were signiﬁcantly different from those of the 9
and/or 4 mg smokers. However the difference between 9 and4 mg smoker groups was not signiﬁcant. The results for Group 4
tended to be higher, and the results for Group 9 tended to be lower
than those reported by Shepperd et al. 2009). In a previous study
(Hecht et al., 2005), no signiﬁcant difference in levels of total NNAL,
1-OHP and total nicotine was found among smokers of 16.9 mg FTC
tar cigarettes who were randomly switched to 10.4 and 5.3 mg cig-
arettes. Hecht et al. (2005) found no dose response and thus no
correlation between levels of FTC tars and these three biomarkers.
A change in smoking behavior to adjust for different smoke yields
and to regulate nicotine intake has been offered as an explanation
to the absence of a dose response and of correlation.
Other limitations of studies involving human smokers might in-
clude (a) presence of an interaction between smoking habits and
occupational exposure; (b) non-representative sample population
(subjects); (c) individual metabolism affecting the level of bio-
markers; (d) confounding factors e.g., diet. By conducting the study
in a controlled environment, the inﬂuence of some of the above
mentioned factors has been minimized. This might have contrib-
uted to fulﬁl the objective of the study because correlations were
observed between MLEs and urinary, salivary and plasma biomark-
ers. Another positive aspect of having conﬁned the subjects on a
voluntary basis is that the average measured cigarette data
(17.7–18.8 cig/day) was very close to reported smoking habits
(17 cig/day). It can be assumed that the clinical approach, while
Table 6
Linear regression analysis data.
Comparison n Slope (95% CI) Slope SE Intercept (95% CI) Intercept SE r (95% CI)
Total Male Female
TNeq vs nicotine MLE 139 0.48 (0.42–0.54) 0.03 1.26 (-0.69–3.21) 0.99 0.80 (0.74–0.86) 0.77 (0.67–0.84) 0.85 (0.76–0.91)
Plasma cotinine vs nicotine MLE 0700 h 139 6.2 (4.9–7.5) 0.6 64 (21–106) 21 0.63 (0.52–0.72) 0.62 (0.48–0.74) 0.64 (0.44–0.78)
Plasma cotinine vs nicotine MLE 1700 h 139 6.8 (5.6–8.0) 0.6 52 (12–92) 20 0.68 (0.58–0.76) 0.67 (0.54–0.77) 0.70 (0.52–0.81)
Salivary cotinine vs nicotine MLE 0700 h 139 6.9 (5.3–8.5) 0.8 58.4 (7–110) 26 0.60 (0.48–0.69) 0.56 (0.40–0.69) 0.62 (0.42–0.77)
Salivary cotinine vs nicotine MLE 1700 h 139 8.0 (6.4–9.5) 0.8 54 (4–103) 25 0.66 (0.56–0.75) 0.65 (0.51–0.76) 0.65 (0.46–0.79)
3-HPMA vs acrolein MLE 139 1.0 (0.9–1.1) 0.1 152 (-136–440) 146 0.77 (0.70–0.83) 0.73 (0.61–0.81) 0.82 (0.70–0.90)
1-OHP vs pyrene MLE 138 0.15 (0.11–0.19) 0.02 120 (59–180) 31 0.44 (0.29–0.56) 0.34 (0.14–0.51) 0.58 (0.37–0.74)
Saliva cotinine 0700 h vs Plasma cotinine 139 1.1 (1.1, 1.2) 0.03 -17 (-33, -1) 8.2 0.96 (0.94–0.97) 0.96 (0.93–0.97) 0.95 (0.92–0.97)
Saliva cotinine 1700 h vs Plasma cotinine 139 1.2 (1.1, 1.2) 0.02 -8.7 (-22, 4.4) 6.6 0.97 (0.96–0.98) 0.98 (0.97–0.99) 0.96 (0.94–0.98)
Plasma cotinine 0700 h vs Tneq 139 10 (8, 12) 1.1 92 (54, 130) 19 0.62 (0.50–0.71) 0.63 (0.48–0.74) 0.57 (0.35–0.73)
Plasma cotinine 1700 h vs Tneq 139 11 (9, 13) 1.1 85 (48, 122) 19 0.66 (0.55–0.74) 0.67 (0.54–0.77) 0.60 (0.39–0.75)
Saliva cotinine 0700 h vs Tneq 139 11 (9, 14) 1.3 87 (41, 133) 23 0.59 (0.47–0.69) 0.58 (0.43–0.71) 0.56 (0.34–0.73)
Saliva cotinine 1700 h vs Tneq 139 13 (10, 15) 1.3 94 (48, 140) 23 0.63 (0.52–0.72) 0.65 (0.50–0.75) 0.57 (0.35–0.73)
Tneq vs nicotine yield 139 5.8 (2.4, 9.2) 1.7 11 (8, 14) 1.5 0.29 (0.13–0.43) 0.35 (0.15–0.52) 0.27 (-0.01–0.51)
CI: conﬁdence interval; SE: standard error.
Table 7
Correlation coefﬁcients of MLE and ISO NFDPM with
various human exposure parameters.
Parameters MLE ISO
Mouth level exposure
Nicotine 0.97 0.23
Acrolein 0.98 0.24
Pyrene 0.97 0.29
Tar n/a# 0.32
Biomarkers
Tneq 0.81 0.30
NNAL 0.67 0.14
3-HPMA 0.80 0.24
1-OHP 0.50 0.06
Saliva cotinine 0.64 0.23
Plasma cotinine 0.66 0.20
# Not applicable.
Table 8
Mean and standard deviation (S.D.) of MLE and biomarkers data per gender and
group. P values, as determined by ANCOVA, are indicated in brackets below each
parameter.
Parameters Group Male Female
Mean ±S.D. Mean ±S.D.
Nicotine MLE (mg/24hr) 14 37 9 30 8
(0.967) 9 33 10 27 9
4 30 10 24 10
Tneq (mg/24hr) 14 21 5 16 5
(0.556) 9 16 6 14 6
4 15 6 12 5
Saliva cotinine (ng/ml)) 14 354 128 305 81
(0.647) 9 318 95 267 142
4 273 133 250 93
Plasma cotinine (ng/ml) 14 307 109 269 61
(0.670) 9 267 79 233 105
4 246 117 231 89
NNAL (ng/ml) 14 284 124 206 70
(0.854) 9 199 90 139 102
4 235 122 157 65
Acrolein MLE (lg/24hr) 14 2425 592 2004 511
(0.788) 9 1912 619 1560 514
4 2009 747 1556 705
3-HPMA (lg/24hr) 14 2823 775 2016 729
(0.835) 9 2103 939 1508 657
4 2167 772 1486 473
Pyrene MLE (ng/24hr) 14 1649 433 1320 376
(0.610) 9 1354 417 1124 339
4 1279 359 1053 373
1-OHP (ng/24hr) 14 371 121 320 121
(0.276) 9 303 109 235 109
4 389 227 279 82
NFDPM MLE (mg/24hr) 14 350 89 279 81
(0.923) 9 258 89 209 72
4 264 98 195 84
Cigarettes per day 14 18 4 17 3
9 19 6 17 5
4 19 4 17 5
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col, did not modify smoking habits (Hatsukami et al. 2009). No sig-
niﬁcant increasing trend of the daily consumption of cigarettes for
low yield was observed (Table 4) and this is consistent with Höfer
et al. (1991).
Gender differences exist in the exposure to mainstream ciga-
rette smoke emissions (Hee et al., 1995; Höfer et al. 1991; Melikian
et al. 2007). For instance, plasma nicotine values were up to 1.7
times higher in male than in female subjects (Höfer et al. 1991).
Emissions of mainstream smoke carcinogens from cigarettes
smoked by females were lower than those from cigarettes smoked
by males (Melikian et al. 2007). For instance, in European Ameri-
cans, the geometric mean total particulate matter (TPM) was
23.8 mg/cigarette for females vs 33.2 mg/cigarette for males and
the nicotine yield per cigarette was 1.63 mg for females vs 2.02
for males. Côté et al. (2010, this volume) have demonstrated that
human smoked tar and nicotine yields were higher when commer-
cial Canadian cigarettes were smoked by male subjects. In our
study, the various exposure and correlations values, although high-
er in males, were not signiﬁcantly different (Tables 6 and 8). In
Côté et al’s study, 50 to 60 subjects were recruited per product
with gender group quotas to represent proﬁles of consumers of
the products being assessed. Market studies indicate that females
smoke lower yield cigarettes than males (Giovino et al., 1996). In
studies where high percentages of the smokers of the low tar prod-
ucts were male subjects, no dose effect could be detected ((Hecht
et al. 2005 (up to 93% males), Mendes et al. (2008), (ca 70%)).
The present study was conducted with groups containing a high
percentage of male smokers ranging from 59% to 71%, as in group4. This proportion is the reverse of the proportion described in
Côté’s study which was more representative of the market. All of
the above indicate that the gender of the subjects can signiﬁcantly
inﬂuence the level of estimated exposure. However, controlling
gender distribution (e.g., 50/50) could be required if the objective
of the study was to investigate a product not commercially avail-
able. In this case, the outcome of such study should not be biased
A. Morin et al. / Regulatory Toxicology and Pharmacology 61 (2011) S3–S12 S11by any demographic factors because the population that is likely to
smoke the product would not be known beforehand.
We have also observed very weak correlations between ISO tar
yields and any biomarkers or any MLE’s (Table 7) as reported by
Hecht et al. (2005). These ﬁndings support research describing lim-
itations of machine-measured methods (Jarvis et al. 2001) and the
importance of examining human smoking to determine the extent
of exposure (Hatsukami et al., 2004). Furthermore, for any given
machine tar or nicotine yield product, wide variation in ﬁlter anal-
ysis data (Côté et al., 2010 (this volume)) and biomarker data
(Hecht et al. (2005) and Jarvis et al. (2001)) have been reported
as observed in our study (Table 4).
In conclusion, correlations found between data obtained with
the ﬁlter analysis method and data obtained from measuring bio-
markers suggest that the ﬁrst method could be used as an alterna-
tive approach to assess exposure to cigarette smoke. The absence
of a clear dose response between smokers of 9 mg vs 4 mg smokers
might be due to demographics and smoking behavior. It is of par-
amount importance that subjects selected in such studies be repre-
sentative of smokers of the selected tar yield product. In a review
paper on clinical trials methods for evaluation of potential reduced
exposure products (PREPs), it was suggested that the study
population should be representative of the population of smokers
or tobacco users with respect to gender, ethnicity, age and socio-
economic status. Thus, ideally, a clinical study should aim at
recruiting populations of smokers similar to the ones that are likely
to use the products (Hatsukami et al., 2009), provided that there is
prior knowledge about such populations.Conﬂict of interest statement
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